Jaguar Health 2024 revenue $11.7M, up 20% YoY; net loss narrows to $38.5M

Jaguar Health, Inc.

2025-Q1 EPS reported -$16.70 vs consensus -$642.60 ▲ beat (+97.4%)

2024 net revenue of ~$11.7M (prescription+non-prescription+license) increased ~20% from $9.8M in 2023.
Q4 2024 revenue of ~$3.5M rose 13% sequentially and 53% YoY; Mytesi prescription volume up 3.9% in 2024.
Net loss attributable to common shareholders improved to $38.5M from $41.3M in 2023; R&D spend fell $2.1M to $16.5M.
Expects first proof-of-concept results in Q2 2025 for crofelemer in short bowel syndrome and microvillus inclusion disease trials.
FDA meeting scheduled Q2 2025 to discuss Phase 3 OnTarget trial results in breast cancer subgroup.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.